Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™
Claim This Podcastby Practice Point Communications
Podcast Authority
Beta
Podcast Overview
<p>In these podcasts, we dive deep into the world of rare diseases, where every story is unique and every diagnosis a challenge. The episodes highlight the personal journeys of patients and medical professionals as they navigate the complexities of rare conditions. Each episode features expert insights on cutting-edge research, emerging treatments, and the social and emotional aspects of living with a rare disease. These podcasts are your guide to understanding and advocating for those affected by these often misunderstood conditions.</p>
Language
🇺🇲
Publishing Since
1/20/2025
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
Reach the team behind Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
July 23, 2026
Episode 37 - Part 4 - Applying the Evidence: A Case-Based Approach to Adult HLH Management
<p>Using a realistic patient case, this final episode demonstrates how expert clinicians evaluate, diagnose, and manage a patient with suspected adult HLH in real time. Faculty discuss the interpretation of evolving clinical findings, biomarkers, and imaging, while highlighting common diagnostic pitfalls, treatment escalation strategies, and the importance of identifying the underlying trigger. The case illustrates how multidisciplinary decision-making and early intervention can improve outcomes in this complex and rapidly evolving syndrome.</p><p><strong>Launch/Release Date:</strong> July 23, 2026 </p><p><strong>Activity Expiration Date:</strong> June 30, 2027</p><p></p><p>Faculty</p><p><strong>Sarah Nikiforow, MD, PhD</strong></p><p>Assistant Professor, Stem Cell Transplantation </p><p>Medical Director, DFCI Cell Manipulation Core Facility </p><p>Technical Director, DFCI Immune Effector Cell Therapy Program </p><p>Dana-Farber Cancer Institute</p><p></p><p><strong>Daniella Schwartz, MD</strong></p><p>Assistant Professor </p><p>Division of Rheumatology and Clinical Immunology </p><p>Departments of Medicine and Immunology </p><p>Co-Director, Autoinflammatory Center of Excellence </p><p>Co-Director, Pittsburgh Immunogenetics Discovery Center </p><p>University of Pittsburgh Medical Center</p><p></p><p>This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.practicepointcme.com/CMEHome/adult-hlh-podcasts-practical-insights-for-diagnosing-and-managing">this link</a> prior to listening to this podcast.</p>
July 23, 2026
Episode 36 - Part 3 - Managing Adult HLH: Trigger-Based Treatment and Emerging Therapeutic Strategies
<p>Successful management of adult HLH requires simultaneous control of hyperinflammation and identification of the underlying trigger. In this episode, faculty review practical treatment approaches, including corticosteroids, targeted immunomodulatory therapies, and selective use of etoposide-based regimens, while highlighting the growing role of pathway-directed therapies. The discussion emphasizes multidisciplinary care, ongoing reassessment, and individualized treatment decisions based on disease biology and clinical response.</p><p><strong>Launch/Release Date:</strong> July 23, 2026 </p><p><strong>Activity Expiration Date:</strong> June 30, 2027</p><p></p><p>Faculty</p><p><strong>Sarah Nikiforow, MD, PhD</strong></p><p>Assistant Professor, Stem Cell Transplantation </p><p>Medical Director, DFCI Cell Manipulation Core Facility </p><p>Technical Director, DFCI Immune Effector Cell Therapy Program </p><p>Dana-Farber Cancer Institute</p><p></p><p><strong>Daniella Schwartz, MD</strong></p><p>Assistant Professor </p><p>Division of Rheumatology and Clinical Immunology </p><p>Departments of Medicine and Immunology </p><p>Co-Director, Autoinflammatory Center of Excellence </p><p>Co-Director, Pittsburgh Immunogenetics Discovery Center </p><p>University of Pittsburgh Medical Center</p><p></p><p>This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.practicepointcme.com/CMEHome/adult-hlh-podcasts-practical-insights-for-diagnosing-and-managing">this link</a> prior to listening to this podcast.</p>
July 23, 2026
Episode 35 - Part 2 - Recognizing Adult HLH Earlier: Clinical Clues and Biomarkers That Matter
<p>Early recognition is critical to improving outcomes in adult HLH. This episode explores the clinical features, common triggers, and laboratory abnormalities that should raise suspicion for HLH, while reviewing the strengths and limitations of current diagnostic tools, including the HLH-2004 criteria, HScore, and emerging biomarker strategies. Faculty also discuss how trends in ferritin and immune biomarkers can support earlier diagnosis and more informed risk stratification.</p><p><strong>Launch/Release Date:</strong> July 23, 2026 </p><p><strong>Activity Expiration Date:</strong> June 30, 2027</p><p></p><p>Faculty</p><p><strong>Sarah Nikiforow, MD, PhD</strong></p><p>Assistant Professor, Stem Cell Transplantation </p><p>Medical Director, DFCI Cell Manipulation Core Facility </p><p>Technical Director, DFCI Immune Effector Cell Therapy Program </p><p>Dana-Farber Cancer Institute</p><p></p><p><strong>Daniella Schwartz, MD</strong></p><p>Assistant Professor </p><p>Division of Rheumatology and Clinical Immunology </p><p>Departments of Medicine and Immunology </p><p>Co-Director, Autoinflammatory Center of Excellence </p><p>Co-Director, Pittsburgh Immunogenetics Discovery Center </p><p>University of Pittsburgh Medical Center</p><p></p><p>This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.practicepointcme.com/CMEHome/adult-hlh-podcasts-practical-insights-for-diagnosing-and-managing">this link</a> prior to listening to this podcast.</p>
37 total episodes available
Deep-dive analytics for Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™?
<p>In these podcasts, we dive deep into the world of rare diseases, where every story is unique and every diagnosis a challenge. The episodes highlight the personal journeys of patients and medical professionals as they navigate the complexities of rare conditions. Each episode features expert insights on cutting-edge research, emerging treatments, and the social and emotional aspects of living with a rare disease. These podcasts are your guide to understanding and advocating for those affected by these often misunderstood conditions.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.